



**LIBRARIES**  
UNIVERSITY OF WISCONSIN - MADISON

## Niamid advertisement.

[s.l.]: [s.n.], 1955

<https://digital.library.wisc.edu/1711.dl/4VGS5OL5ISKUI9D>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



# NIAMID<sup>®</sup>

## reduces pain in angina pectoris

**NIAMID**, in intensive clinical tests, has proved to have a high degree of safety and to be a valuable adjunct in the management of the anginal syndrome. NIAMID produces striking symptomatic improvement in angina patients...

- reduces frequency of anginal episodes
- diminishes severity of attacks
- decreases nitroglycerin requirements
- renews sense of well-being

*Note:* Because of dramatic relief of symptoms and increased sense of well-being in anginal cases, it is advisable to caution the patient against overexertion.

**DOSAGE:** Start with 75 mg. of NIAMID daily in single or divided doses. After 2 weeks or more, adjust the dosage, depending upon patient response, in steps of one or one-half 25 mg. tablet. Once improvement is seen, gradually reduce dosage to the maintenance level. Many patients respond to NIAMID within a few days, others within 7 to 14 days. NIAMID is available as 25 mg. (pink) and 100 mg. (orange) scored tablets.

*A Professional Information Booklet giving detailed information on NIAMID is available on request from the Medical Department, Pfizer Laboratories, Division, Chas. Pfizer & Co., Inc., Brooklyn 6, N. Y.*

\*Trademark for nialamide

**Pfizer** Science for the world's well-being™

